中华劳动卫生职业病杂志
中華勞動衛生職業病雜誌
중화노동위생직업병잡지
CHINESE JOURNAL OF INDUSTRIAL HYGIENE AND OCCUPATIONAL DISEASES
2013年
5期
386-388
,共3页
吴晓晖%蔡闯%徐俭朴%汝触会%何飞
吳曉暉%蔡闖%徐儉樸%汝觸會%何飛
오효휘%채틈%서검박%여촉회%하비
矽肺%哮喘%治疗结果
矽肺%哮喘%治療結果
석폐%효천%치료결과
Sillicosis%Asthma%Treatment Outcome
目的 探讨沙美特罗替卡松干粉联合噻托溴铵粉吸入对矽肺并发哮喘的疗效.方法 将30例矽肺并发哮喘的患者随机分为沙美特罗替卡松单药治疗组(单药组)14例,沙美特罗替卡松联合噻托溴铵联合治疗组(联合治疗组)16例.单药治疗组给予沙美特罗替卡松(50μg,2次/d)吸入治疗,联合治疗组给予沙美特罗替卡松(50 μg,2次/d)联合噻托溴铵(18μg,1次/d)吸入治疗,疗程6个月.测定肺功能和进行哮喘控制测试(ACT评分)评分,并进行比较.结果 两组治疗前FEV1.0/FVC(％)、FEV1.0(％)、FEV1.0及ACT评分比较,差异均无统计学意义(P＞0.05).两组治疗后FEV1.0/FVC(％)、FEV1.0％、FEV1.0及ACT评分均明显高于治疗前,差异有统计学意义(P＜0.01).与单药组比较,联合治疗组治疗后FEV1.0/FVC(％)和ACT评分明显升高,差异有统计学意义(P＜0.05).联合治疗组急性发作次数[每人每月(0.98±0.79)次]明显低于单药组[每人每月(2.10±0.81)次],差异有统计学意义(t=3.86,P＜0.05).两组均无明显不良反应发生.结论 沙美特罗替卡松或沙美特罗替卡松联合噻托溴铵均能改善矽肺并发哮喘的肺通气功能及哮喘症状,沙美特罗替卡松联合噻托溴铵联合治疗效果更好.
目的 探討沙美特囉替卡鬆榦粉聯閤噻託溴銨粉吸入對矽肺併髮哮喘的療效.方法 將30例矽肺併髮哮喘的患者隨機分為沙美特囉替卡鬆單藥治療組(單藥組)14例,沙美特囉替卡鬆聯閤噻託溴銨聯閤治療組(聯閤治療組)16例.單藥治療組給予沙美特囉替卡鬆(50μg,2次/d)吸入治療,聯閤治療組給予沙美特囉替卡鬆(50 μg,2次/d)聯閤噻託溴銨(18μg,1次/d)吸入治療,療程6箇月.測定肺功能和進行哮喘控製測試(ACT評分)評分,併進行比較.結果 兩組治療前FEV1.0/FVC(％)、FEV1.0(％)、FEV1.0及ACT評分比較,差異均無統計學意義(P＞0.05).兩組治療後FEV1.0/FVC(％)、FEV1.0％、FEV1.0及ACT評分均明顯高于治療前,差異有統計學意義(P＜0.01).與單藥組比較,聯閤治療組治療後FEV1.0/FVC(％)和ACT評分明顯升高,差異有統計學意義(P＜0.05).聯閤治療組急性髮作次數[每人每月(0.98±0.79)次]明顯低于單藥組[每人每月(2.10±0.81)次],差異有統計學意義(t=3.86,P＜0.05).兩組均無明顯不良反應髮生.結論 沙美特囉替卡鬆或沙美特囉替卡鬆聯閤噻託溴銨均能改善矽肺併髮哮喘的肺通氣功能及哮喘癥狀,沙美特囉替卡鬆聯閤噻託溴銨聯閤治療效果更好.
목적 탐토사미특라체잡송간분연합새탁추안분흡입대석폐병발효천적료효.방법 장30례석폐병발효천적환자수궤분위사미특라체잡송단약치료조(단약조)14례,사미특라체잡송연합새탁추안연합치료조(연합치료조)16례.단약치료조급여사미특라체잡송(50μg,2차/d)흡입치료,연합치료조급여사미특라체잡송(50 μg,2차/d)연합새탁추안(18μg,1차/d)흡입치료,료정6개월.측정폐공능화진행효천공제측시(ACT평분)평분,병진행비교.결과 량조치료전FEV1.0/FVC(％)、FEV1.0(％)、FEV1.0급ACT평분비교,차이균무통계학의의(P＞0.05).량조치료후FEV1.0/FVC(％)、FEV1.0％、FEV1.0급ACT평분균명현고우치료전,차이유통계학의의(P＜0.01).여단약조비교,연합치료조치료후FEV1.0/FVC(％)화ACT평분명현승고,차이유통계학의의(P＜0.05).연합치료조급성발작차수[매인매월(0.98±0.79)차]명현저우단약조[매인매월(2.10±0.81)차],차이유통계학의의(t=3.86,P＜0.05).량조균무명현불량반응발생.결론 사미특라체잡송혹사미특라체잡송연합새탁추안균능개선석폐병발효천적폐통기공능급효천증상,사미특라체잡송연합새탁추안연합치료효과경호.
Objective To investigate Salmeterol/FluticasonePropionate and Totropiumi treatment of Sillicosis merger Asthma.Methods 30 patients with Sillicosis merger Asthma were randomly divided into group Salmeterol/Fluticasone Propionate(Single group) (n=14) and group Salmeterol/Fluticasone Propionate and Totropiumi (Joint group)(n=16),patient in single group were only given Salmeterol/FluticasonePropionate (50 μg Bid) inhaling,and those in Joint group were given Salmeterol/FluticasonePropionate (50 μg Bid) and Totropiumi (18 μg Qd) inhaling.The treatment was last for 6 months.Before the treatment,evaluation of the two groups of Sillicosis installment,determination their foungation lung function and ACT score..After the cause of treatment,lung function FEV1.0/FVC (％),FEV1.0 pred％,FEV1.0(ml),ACT score,the incidence of side effects of two groups were compared and analyzed.Result The two groups before the treatment of lung fuction and ACT score had no statistically significant difference.The two groups after treatment of lung fuction FEV1.0/FVC (％),FEV1.0 pred％,ACT score obviously higher than before treatment (P＜0.05),Joint group in FEV 1/FVC (％),ACT score significantly higher than in Single group (P＜0.05),Joint group acute attack times (0.98±0.79)/time lower than Single group (2.10±0.81)/time (t=3.86,P＜0.05).There were no significant side effect in two groups.Conclusion Salmeterol/Fluticasone Propionate or the combination of Salmeterol/Fluticasone Propionate and Totropiumi can improve lung function and clinical symptoms of patients with Sillicosis merger Asthma.It is also better that the combination of Salmeterol/Fluticasone Propionate and Totropiumi obviously improve clinical symptoms of patients and reduice acute attack times.
